Awaiting development: Guidance and quality standards
Showing 1 to 3 of 3
| Title | Type |
|---|---|
| Selinexor for maintenance treatment of p53 wild-type advanced or recurrent endometrial cancer after systemic treatment [TSID12374] | Technology appraisal guidance |
| Selinexor with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 to 4 treatment lines in people who have not had pomalidomide [ID6705] | Technology appraisal guidance |
| Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [ID6717] | Technology appraisal guidance |